Arch Fam Med
Institution: CLOCKSS  | My Account | E-mail Alerts | Access Rights | Sign In
  Vol. 3 No. 6, June 1994 TABLE OF CONTENTS
 • Online Features
  Clinical Reviews
 This Article
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (21)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal

Selected Factors That Influence Responses to Antihypertensives

Choosing Therapy for the Uncomplicated Patient

Barry L. Carter, PharmD; Edward D. Frohlich, MD; William J. Elliott, MD, PhD; Michael A. Moore, MD; R. Jerry Mann, MD; Raymond W. Roberts, PharmD

Arch Fam Med. 1994;3(6):528-535.

Article references have been provided for searching and linking. Additional reference information may be available in the article PDF.

1. Joint National Committee on Detection, Evaluation, and Treatment of Hypertension. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153:154-183. FREE FULL TEXT
2. Weber MA, Laragh JH. Hypertension: steps forward and steps backward: the Joint National Committee Fifth Report. Arch Intern Med. 1993;153:149-152. FREE FULL TEXT
3. Frohlich ED. Hypertension. In: Rakel RE. Conn's Current Therapy. Philadelphia, Pa: WB Saunders Co; 1993:280-296.
4. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-3264. FREE FULL TEXT
5. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ. 1992;304;405-412. FREE FULL TEXT
6. Dahlöf B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients With Hypertension (STOP-Hypertension). Lancet. 1991;304:405-412.
7. Sever P, Beevers G, Bulplitt C, et al. Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society. BMJ. 1993;306:983-987. FREE FULL TEXT
8. Carter BL, Butler CD, Bakht F, Miller JW. Decision analysis as a quality-assurance screening tool. Fam Med. 1992;24:362-367. PUBMED
9. Carter BL, Butler CD, Rogers JC, Holloway RL. Evaluation of physician decision making with the use of prior probabilities and a decision-analysis model. Arch Fam Med. 1993;2:529-534. FREE FULL TEXT
10. Materson BJ, Reda DJ, Cushman WC, et al. Singledrug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med. 1993;328:914-921. PUBMED
11. Freis ED. Age and antihypertensive drugs (hydrochlorothiazide, bendroflumethiazide, nadolol and captopril). Am J Cardiol. 1988;61:117-121. PUBMED
12. Neaton JD, Grimm RH Jr, Prineas RJ, et al. Treatment of Mild Hypertension Study: final results. JAMA. 1993;270:713-724. FREE FULL TEXT
13. Curb JD, Borhani NO, Schnaper H, et al. Detection and treatment of hypertension in older individuals. Am J Epidemiol. 1985;121:371-376. FREE FULL TEXT
14. Bühler FR, Burkart F, Lütold BE, Küng M, Marbet G, Pfisterer M. Antihypertensive beta blocking action as related to renin and age: a pharmacologic tool to identify pathogenetic mechanisms in essential hypertension. Am J Cardiol. 1975;36:653-669. PUBMED
15. Wikstrand J, Westergren G, Berglund G, et al. Antihypertensive treatment with metoprolol or hydrochlorothiazide in patients aged 60 to 75 years: report from a double-blind international multicenter study. JAMA. 1986;255:1304-1310. FREE FULL TEXT
16. Massie B, MacCarthy EP, Ramanathan KB, et al. Diltiazem and propranolol in mild to moderate essential hypertension as monotherapy or with hydrochlorothiazide. Ann Intern Med. 1987;107:150-157. FREE FULL TEXT
17. Tuck ML, Katz LA, Kirkendall WM, Koeppe PR, Ruoff GE, Sapir DG. Low-dose captopril in mild to moderate geriatric hypertension. J Am Geriatr Soc. 1986;34:693-696. PUBMED
18. Morgan TO, Anderson A, Jones E. Comparison and interaction of low dose felodipine and enalapril in the treatment of essential hypertension in elderly subjects. Am J Hypertens. 1992;5:238-243. PUBMED
19. Bühler F, Kiowski U, Bolli P. Greater antihypertensive efficacy of the calcium channel inhibitor verapamil in older and low renin patients. Clin Sci. 1982;63(suppl_8):439s-442s.
20. Zing W, Ferguson RK, Vlasses PH. Calcium antagonists in elderly and black hypertensive patients: therapeutic controversies. Arch Intern Med. 1991;151:2154-2162. FREE FULL TEXT
21. Howard J, Tiedeman G. The relative effectiveness of antihypertensive drugs in Caucasians and Negroes. Clin Pharmacol Ther. 1967;8:502-520. PUBMED
22. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension, I: results of short-term titration with emphasis on racial differences in response. JAMA. 1982;248:1996-2003. FREE FULL TEXT
23. Saunders E, Weir MR, Kong W, Hollifield J, et al. A comparison of the efficacy and safety of a β-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med. 1990;150:1707-1713. FREE FULL TEXT
24. Cummings DM, Amadio P Jr, Taylor EJ Jr, et al. The antihypertensive response to lisinopril: the effect of age in a predominantly black population. J Clin Pharmacol. 1989;29:25-32. ABSTRACT
25. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Racial differences in response to low-dose captopril are abolished by the addition of hydrochlorothiazide. Br J Clin Pharmacol. 1982;14(suppl 2):97s-101s. PUBMED
26. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Low-dose captopril for the treatment of mild to moderate hypertension, I: results of a 14-week trial. Arch Intern Med. 1984;144:1947-1953. FREE FULL TEXT
27. Caralis PV. Hypertension in the Hispanic-American population. Am J Med. 1990;88(suppl 3B):9S-16S. PUBMED
28. Schoenberger JA, Testa M, Ross A, Brennan WK, Bannon JA. Efficacy, safety, and quality-of-life assessment of captopril antihypertensive therapy in clinical practice. Arch Intern Med. 1990;150:301-306. FREE FULL TEXT
29. Zhou HH, Koshakji RP, Silberstein DJ, Wilkinson GR, Wood AJJ. Racial differences in drug response: altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. N Engl J Med. 1989;320:565-570. PUBMED
30. Zhou HH, Adedoyin A, Wood AJJ. Differing effect of atropine on heart rate in Chinese and white subjects. Clin Pharmacol Ther. 1992;52:120-124. PUBMED
31. Jones DW, Sands CD. Treatment of essential hypertension in Asians: enalapril as monotherapy versus combination therapy with hydrochlorothiazide. Pharmacotherapy. 1991;11:127-130. PUBMED
32. Hume AL, Barbour MM, Willey CJ, Assaf AR, Lapane KL, Carleton RA. Changing trends in antihypertensive therapy in two New England communities during the 1980s. Pharmacotherapy. 1993;13:244-251. PUBMED
33. Applegate WB, Phillips HL, Schnaper H, et al. A randomized controlled trial of the effects of three antihypertensive agents on blood pressure control and quality of life in older women. Arch Intern Med. 1991;151:1817-1823. FREE FULL TEXT
34. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? a novel assessment technique. JAMA. 1989;261:3273-3277. FREE FULL TEXT
35. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med. 1990;150:1881-1884. FREE FULL TEXT
36. Allen JH, McKenney JM, Stratton MA, Link K. Antihypertensive effect of hydrochlorothiazide administered once or twice daily. Clin Pharm. 1982;1:239-243. PUBMED
37. Hornung RS, Jones RI, Gould BA, Sonecha T, Raftery EB. Twice-daily verapamil for hypertension: a comparison with propranolol. Am J Cardiol. 1986;57(suppl D):93D-98D. PUBMED
38. Lopez LM, Gefter ML, Hemmes RJ. Once-daily propranolol for hypertension. Drug Intell Clin Pharm. 1984;18:812-815. ABSTRACT
39. Carter BL, Gersema LM, Williams GO, Schabold K. Once-daily propranolol for hypertension: a comparison of regular-release, long-acting, and generic formulations. Pharmacotherapy. 1989;9:17-22. PUBMED
40. Schoenberger JA, Wilson DJ. Once-daily treatment of essential hypertension with captopril. J Clin Hypertens. 1986;4:379-387.
41. Frishman W, Shiomo C, Kimmel B, et al. Twicedaily administration of oral verapamil in the treatment of essential hypertension. Arch Intern Med. 1986;146:561-565. FREE FULL TEXT
42. Carter BL, Noyes MA, Demmler RW. Differences in serum concentrations of and responses to generic verapamil in the elderly. Pharmacotherapy. 1993;13:359-368. PUBMED
43. Schwartz JB, Keefe DL, Kirsten E, Kates RE, Harrison DC. Prolongation of verapamil elimination kinetics during chronic oral administration. Am Heart J. 1982;104;198-203. PUBMED
44. Abernethy DR, Schwartz JB, Todd EL, Luchi R, Snow E. Verapamil pharmacodynamics and disposition in young and elderly hypertensive patients: altered electrocardiographic and hypotensive responses. Ann Intern Med. 1986;105:329-336. FREE FULL TEXT
45. Rocci ML, Vlasses PH, Cressman MD, Sirgo MA, Plachetka JR. Pharmacokinetics and pharmacodynamics of labetalol in elderly and young hypertensive patients following single and multiple doses. Pharmacotherapy. 1990;10:92-99. PUBMED
46. Wainer IW. Three-dimension view of pharmacology. Am J Hosp Pharm. 1992;49(suppl 1):S4-S8. ABSTRACT
47. Gilmore DS, Gal J, Gerber JG, Nies AS. Age and gender influence the stereoselective pharmacokinetics of propranolol. J Pharmacol Exp Ther. 1992;261:1181-1186. FREE FULL TEXT
48. Hoon TJ, Bauman JL, Rodvold KA, Gallestegui J, Hariman RJ. The pharmacodynamic and pharmacokinetic differences of the d- and l-isomers of verapamil: implications in the treatment of paroxysmal supraventricular tachycardia. Am Heart J. 1986;112:396-403. PUBMED
49. Echizen H, Brecht T, Niedergesäss S, Vogelgesang B, Eichelbaum M. The effect of dextro-, levo-, and racemic verapamil on atrioventricular conduction in humans. Am Heart J. 1985;109:210-217. PUBMED
50. Echizen H, Vogelgesang B, Eichelbaum M. Effects of d,l-verapamil on atrioventricular conduction in relation to its stereoselective firstpass metabolism. Clin Pharmacol Ther. 1985;38:71-76. PUBMED
51. Schwartz JB, Troconiz IF, Verotta D, Liu S, Capili H. Aging effects on stereoselective pharmacokinetics and pharmacodynamics of verapamil. J Pharmacol Exp Ther. 1993;265:690-698. FREE FULL TEXT
52. Sahajwalla CG, Longstreth J, Karim A, et al. Bioavailability-bioequivalence of Calan SR, verapamil CR and Calan-IR based on R-, S- and R, Sverapamil. J Clin Pharmacol. 1992;32:961-962.
53. Baba T, Murabayashi S, Aoyagi K, Ishizaki T. Effects of dilevalol, an R, R-isomer of labetalol, on blood pressure and renal function in patients with mild-to-moderate essential hypertension. Eur J Clin Pharmacol. 1988;35:9-15. PUBMED
54. Wallin JD, Cook E, Clifton GG, Blasucci DJ, Poland M. Intravenous dilevalol: effects of the R-R optical isomer of labetalol in patients with severe hypertension. Arch Intern Med. 1988;148:534-538. FREE FULL TEXT
55. Sepracor files for enantiomeric beta-blocker. Chem Eng News. 1991:69:16.